AstraZeneca paid $100 million upfront to outlicense ex‑China rights for Jacobio Pharmaceuticals’ phase I pan‑KRAS inhibitor JAB‑23E73 in a deal that can total roughly $1.9 billion. AstraZeneca will lead global development and commercialization outside China while the firms collaborate in China, a structure that accelerates access to a broad KRAS targeting program. The asset adds to AstraZeneca’s oncology holdings in a competitive KRAS landscape and demonstrates big‑pharma appetite for China‑originated oncology assets. Jacobio will receive development and commercial milestones plus tiered royalties, bolstering its balance sheet for continued China development and earlier‑stage pipeline work. Investors and competitors will watch clinical progression closely: pan‑KRAS inhibitors aim to address multiple KRAS mutations across tumor types, and a successful development would expand options for patients with KRAS‑driven cancers.